USD 68 million in export contracts for biotech drugs, etc. - USD 88 million in export contracts to Europe in
the past two years – Dong-A Pharmaceutical (CEO Kim, Won-Bae) signed five-year export contracts worth
USD 68 million for biotech and specialty drugs with five companies in three eastern European countries
(Turkey, Russia, and Ukraine). The export products are biotech drugs developed by Dong-A’s genetic
engineers and manufactured at the company’s facilities. The drugs include Gonadopin®, an infertility
treatment, Growtropin®, a growth hormone, Leucostim®, a treatment for neutropenia, Eporon®, a
hematinic drug, Interferon Alpha®, an antitumor agent, Gemcit®, an anticancer drug, and Closerin®, a
tuberculosis treatment.




On August 13, Dong-A signed a USD 7.5 million export agreement with the Ukrainian company L-Contract for
Growtropin®, Gemcit®, and Closerin®, and a USD 2.4 million agreement with AllMed for Interferon
Alpha®. These agreements will allow Dong-A to export about USD 10 million of biotech drugs to the Ukraine
over a five-year period. Dong-A also revealed on the 13th that it signed export agreements with Russian and
Turkish drug companies in June and July. In June, agreements were signed with the Turkish companies Dr.
Frik (USD 6 million, five-year contract for Gonadopin®) and DEM ilac (USD 16.2 million contract for
Gemcit®), and with Russia’s MIR Pharm (USD 16 million contract for Gonadopin®).




In July, a three-year contract with DEM ilac for Leucostim® and Eporon® (USD 10 million each) that was
signed last year was extended for two more years, which will allow USD 10 million of extra exports for each
of the two products. Dong-A’s total exports to Turkey over five years are expected to reach USD 62.2 million
(USD 46 million for biotech drugs and USD 16.2 million for specialized drugs). In Russia, the inflow of oil
money has caused the government to expand public healthcare services, and the market for medical products
is expanding rapidly.




In light of this trend, Dong-A has aggressively targeted Russia’s pharmaceutical market, and is now in export
negotiations for another biotech drug with the country’s largest drug company. Dong-A’s entry into the eastern
European market shows that Dong-A’s biotech drugs were approved by the region’s strict quality norms and
advanced GMP standards. Dong-A’s export of high value-added biotech drugs shows that Korea can go
beyond exporting only antibiotics and basic drug products. CEO Kim, Won-Bae said “Turkey, which is in talks
to enter the EU, is already using the Common Technical Document, Europe’s registration system for medical
products, and is approving biotech drugs based on European standards (EU-GMP). This contract will help us
enter the EU market and globalize our company.” Dong-A is also negotiating to export biotech drugs to the CIS
region, and is preparing to enter the EU’s KRW 17 trillion biotech drug market in anticipation of a Korea-EU
free-trade agreement.




*CTD Format: The CTD format is an international format for registering medical/drug products in Europe, the US,
and Japan. The standardized format is easier to process.